The growth of the market can be majorly attributable to the growing incidence and prevalence of PJIA Around 300,000 children in the U.S. have a form of JIA. Juvenile idiopathic arthritis (JIA) is a chronic inflammatory disease involving inflammation of one or more joints in children under the age of 16 years. JIA is considered as one of the most common arthritis types in kids and teens, and includes six categories: systemic, oligoarticular, polyarticular, enthesitis-related, psoriatic, and undifferentiated. It begins before 16 years of age and persists for at least six weeks. The risk and prevalence of JIA is slightly higher in girls
The International League of Associations for Rheumatology (ILAR) defined polyarticular JIA as the arthritis affecting five or more joints during the first six months of the disease. It is the second largest disease manifestation with an estimated prevalence of 25%, next only to oligoarticular disease (45%). PJIA is further classified based the presence of rheumatoid factor into RF-negative and RF-positive. Polyarticular juvenile idiopathic arthritis (PJIA) affects both the small joints of the hands and feet, and large joints like the knees, hips and ankles. PJIA majorly causes inflammation in small joints of the fingers, but weight-bearing joints and the jaw can also be affected. Symptoms include fevers, pink rash, eye inflammation, joint pain, joint swelling and problems with bone development and growth. JIA is mostly treated with a combination of medications, exercise and physical therapy and requires joint surgeries in rare cases. Disease-modifying anti-rheumatic drugs (DMARDs) such as sulfasalazine, methotrexate, hydroxychloroquine and leflunomide are the first drugs administered to kids with JIA. Nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids and biologics are the other key medications used in the treatment of JIA.
Market Dynamics
Drivers
- Increasing prevalence of polyarticular juvenile idiopathic arthritis
- Development of biosimilars
Restraints
- Side effects associated with medications
Increasing prevalence of polyarticular juvenile idiopathic arthritis
Increasing prevalence of polyarticular juvenile idiopathic arthritis is the primary factor for the growth of the PJIA drugs market. Juvenile idiopathic arthritis occurs when the immune system attacks its own cells and tissues in the body. The major causes for the disease are not clinically known. However, heredity and environment are considered to play a role in the occurrence of JIA.
JIA evolved as the largest type of arthritis among children and polyarticular JIA is estimated to account for nearly 25% of the overall JIA cases globally. In the U.S., approximately 300,000 children are estimated to have some type of arthritis. The estimated incidence rate for JIA range from 4-14 cases per 100,000 children annually. The prevalence rate is greatly varying by race and location. Countries such as Nigeria, India, South Africa and Turkey are experiencing highest occurrence of PJIA in the world.Also, the incidence of PJIA is estimated to significantly grow over the near future owing to increasing awareness towards the condition and their diagnosis. Polyarticular RF negative in particular is increasing its incidence rate globally, with average frequency of nearly 20%. Polyarticular RF positive accounts for 5% of the total JIA cases.
Geographical Analysis
The North America market is estimated to grow at a CAGR of XX% during the forecast period (2020-2027) to reach a market value of USD XX million by 2027. The North America region is dominating the global polyarticular juvenile idiopathic arthritis drugs market accounted for the largest market share in 2019, owing to rising prevalence of juvenile idiopathic arthritis and increasing development of drugs for the treatment of polyarticular juvenile idiopathic arthritis. For instance, in April 2020, the Janssen Pharmaceutical Companies of Johnson & Johnson submitted the two supplemental Biologics License Applications (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of SIMPONI ARIA® (golimumab) for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) and juvenile psoriatic arthritis (jPsA), in patients two years of age and older in combination with methotrexate. Also, in May 2018, Genentech received the US Food and Drug Administration (FDA) approval for subcutaneous formulation of tocilizumab (Actemra) as treatment for active polyarticular juvenile idiopathic arthritis (PJIA) in patients 2 years of age and older.
The North American market is expected to grow, owing to the increasing lifestyle changes, an increasing number of obesity cases, and an extensive rise in the geriatric population in North America. As a result, the adoption of treatment and drugs is also increasing in the region. Approximately 300,000 children in the United States are estimated to have some type of arthritis. The incidence rate estimates for JIA range from 4-14 cases per 100,000 children annually; for JRA, the prevalence has ranged from 1.6 to 86.1 cases per 100,000. Hence, the increasing incidence of juvenile idiopathic arthritis (JIA )is leading to a rise in research and development for its treatment by private manufacturers and research organizations. Several clinical trials are undergoing to expand the potential future of PJIA drugs. For instance, in September 16, 2018, Genentech, a member of the Roche Group announced that the U.S. Food and Drug Administration (FDA) has approved the subcutaneous (SC) formulation of Actemra® (tocilizumab) for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients two years of age and older. However, strict regulatory scenarios by FDA for product approval will hamper the growth of the polyarticular juvenile idiopathic arthritis drugs market during the forecast period. The developed countries like the US and Canada have a structured healthcare system which has a fast adoption rate for newer drugs, therapies, and technologies. Hence, expenditure on Polyarticular juvenile idiopathic arthritis drugs is expected to increase with increasing prevalence in the region.